Co-Authors
This is a "connection" page, showing publications co-authored by VIJAY NAMBI and SANKAR NAVANEETHAN.
Connection Strength
0.792
-
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD. J Am Soc Nephrol. 2025 Jan 01; 36(1):87-98.
Score: 0.230
-
Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. Am J Kidney Dis. 2021 11; 78(5):700-708.e1.
Score: 0.183
-
Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. Am J Kidney Dis. 2020 06; 75(6):935-945.
Score: 0.169
-
Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. J Am Coll Cardiol. 2024 May 07; 83(18):1824-1826.
Score: 0.056
-
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
Score: 0.053
-
Heart Failure-Type Symptom Score Trajectories in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2023 04; 81(4):446-456.
Score: 0.051
-
Heart failure-type symptom scores in chronic kidney disease: The importance of body mass index. Int J Obes (Lond). 2022 10; 46(10):1910-1917.
Score: 0.050